Effekt der Rote-Hand-Briefe zu Citalopram und Escitalopram auf Verordnungszahlen bei der stationären Behandlung von Angsterkrankungen

Köberle, Ursula; Grohmann, Renate; Belz, Michael; Greil, Waldemar und Degner, Detlef (2022): Effekt der Rote-Hand-Briefe zu Citalopram und Escitalopram auf Verordnungszahlen bei der stationären Behandlung von Angsterkrankungen. In: Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz, Bd. 65, Nr. 11: S. 1204-1212

Abstract

Background In 2011, direct healthcare professional communication (DHPC) letters on citalopram and escitalopram were sent out to address the risk of QTc prolongation in the ECG. Healthcare professionals were informed about a reduction of the maximum recommended daily dose. Furthermore, a contraindication for QTc-prolonging co-medication was given. Previous studies noted that these instructions were implemented incompletely. Aim For the first time, this study analyzed how the DHPC affected the prescription of citalopram and escitalopram in patients with anxiety disorders. Methods Drug utilization data from the project Arzneimittelsicherheit in der Psychiatrie e. V. (AMSP) was used to examine whether the proportion of patients treated with a higher-than-recommended daily dose (high dose) and the proportion of patients with QTc-prolonging co-medication would decrease post-DHPC (combined category of citalopram/escitalopram). Results Drug utilization data of n = 364 patients pre- and n = 262 patients post-DHPC were compared. The proportion of patients with high dose declined from 10.7% to 5.4% (p = 0.019). The proportion of patients with QTc-prolonging co-medication did not change significantly from pre- (54.7%) to post-DHPC (51.5%, p = 0.437). Discussion In accordance with previous studies, the proportion of high-dose patients decreased after DHPC publication while the proportion of patients with QTc-prolonging co-medication remained widely unchanged. The specific recommendation on daily dosage seems to have been better implemented than the broadly formulated contraindication of QTc-prolonging co-medication. Hence, DHPCs should be written precisely and give advice for specific clinical situations.

• Dokumententyp: Zeitschriftenartikel
• Fakultät: Medizin
• Themengebiete: 600 Technik, Medizin, angewandte Wissenschaften > 610 Medizin und Gesundheit
• ISSN: 1436-9990
• Sprache: Deutsch